15:07 , Sep 1, 2017 |  BC Week In Review  |  Company News

CellAct grants Mundiphamra to develop and commercialie rights to CAP7.1

CellAct Pharma GmbH (Dortmund, Germany) granted Mundipharma International Ltd. (Dublin, Ireland) worldwide rights to develop and commercialize CAP7.1 in a deal that CellAct says is valued at more than $250 million. Under the deal, CellAct...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

CAP7: Preliminary Phase II data

Preliminary data from 18 patients with adenocarcinoma arising from bile ducts or the gallbladder in an open-label, German Phase II trial showed that 150 and 200 mg/m 2 CAP7.1 on days 1-5 of a 21-day...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

CAP7: Phase I data

CellAct said that a dose-escalation Phase I trial in 19 patients with heavily pretreated solid tumors showed that 225-1,000 mg/m 2/cycle CAP7.1 had "acceptable" safety and tolerability with "manageable" side effects that were mainly hematological...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

CAP7: Phase I started

CellAct began an open-label, dose-escalation, German Phase I trial to evaluate intravenous CAP7.1 in 30 patients. CellAct Pharma GmbH, Dortmund, Germany   Product: CAP7.1   Business: Cancer   Molecular target: Topoisomerase II (TOP2)   Description: Small molecule...